A study comparing the combined effect of nivolumab plus ipilimumab therapy cause higher grade immune-related adverse events than single agent therapy in melanoma, renal cell carcinoma and lung cancer
Latest Information Update: 10 Jul 2020
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Lung cancer; Malignant melanoma; Renal cell carcinoma
- Focus Therapeutic Use
- 10 Jul 2020 New trial record
- 19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020